FNAM (Evolutionary Genomics) Change In Receivables: $0.00 Mil (TTM As of Dec. 2022)

What is Evolutionary Genomics Change In Receivables?

Evolutionary Genomics FNAM 31 Change In Receivables is $0.00 Mil as of Dec. 2022. GuruFocus rates FNAM with a GF Score™ of 31/100.

Evolutionary Genomics's change in receivables for the quarter that ended in Dec. 2022 was $0.00 Mil. It means Evolutionary Genomics's Accounts Receivable stayed the same from Sep. 2022 to Dec. 2022 .

Evolutionary Genomics's change in receivables for the fiscal year that ended in Dec. 2022 was $0.00 Mil. It means Evolutionary Genomics's Accounts Receivable stayed the same from Dec. 2021 to Dec. 2022 .

Evolutionary Genomics's Accounts Receivable for the quarter that ended in Dec. 2022 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Evolutionary Genomics's liquidation value for the three months ended in Dec. 2022 was $-7.37 Mil.

Evolutionary Genomics (OTCPK:FNAM) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Evolutionary Genomics's Days Sales Outstanding for the quarter that ended in Dec. 2022 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Evolutionary Genomics's accounts receivable are only considered to be worth 75% of book value:

Evolutionary Genomics's liquidation value for the quarter that ended in Dec. 2022 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.577	-	7.946	+	0.75 * 0	+	0.5 * 0
=	-7.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evolutionary Genomics Change In Receivables Related Terms

Evolutionary Genomics Change In Receivables Historical Data

* Premium members only.

The historical data trend for Evolutionary Genomics's Change In Receivables can be seen below:

Evolutionary Genomics Change In Receivables Chart

Evolutionary Genomics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Change In Receivables

Get a 7-Day Free Trial

-0.04

0.03

0.01

0.00

Evolutionary Genomics Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Change In Receivables	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

31GF Score

Evolutionary Genomics Inc FNAM

Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Evolutionary Genomics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Frequently Asked Questions Learn more about Change In Receivables →

What does a Change In Receivables of $0.00 Mil mean?

Evolutionary Genomics (FNAM) has a Change In Receivables of $0.00 Mil as of Dec. 2022. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Evolutionary Genomics and its competitors.

Is Evolutionary Genomics' Change In Receivables too high?

Evolutionary Genomics' current Change In Receivables is $0.00 Mil. Overall, Evolutionary Genomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.

How does Evolutionary Genomics' Change In Receivables compare to BXRX and GNCA?

Evolutionary Genomics' Change In Receivables of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Change In Receivables for a Biotechnology company?

A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Change In Receivables mean?

A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Evolutionary Genomics and its competitors. Evolutionary Genomics's current Change In Receivables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Evolutionary Genomics stock overvalued right now?

Evolutionary Genomics (FNAM) has a current Change In Receivables of $0.00 Mil. The current Change In Receivables is $0.00 Mil. Evolutionary Genomics' overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Change In Receivables calculated?

Change In Receivables is calculated from a company's financial statements. For Evolutionary Genomics (FNAM), the current Change In Receivables is $0.00 Mil as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evolutionary Genomics Business Description

Industry Healthcare Biotechnology

Comparable Companies BXRX GNCA XSNX KPRX HCYT EVFM KRBP TTNP ATXI ISCO OCSE:NOVO B ASX:CSL REGN VRTX MRNA XKRX:207940 BNTX HKSE:02269 SGEN SZSE:300122

Address 4220 Morning Star Drive, Castle Rock, CO, USA, 80108

Website https://www.evolgen.com

Evolutionary Genomics Inc is involved in the development of a technology platform, the Adapted Traits Platform (ATP), to identify commercially valuable genes that control important traits in animals and plants. It uses the ATP to identify genes to improve crop plant traits such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. The company's platform identifies key genes that have changed successfully to impart new or improved traits. Its primary source of revenue had been contract services revenue for research performed by it on behalf of other commercial entities and grant income received from governmental agencies, industry associations and grant-making foundations for research performed.

31GF Score

Get the complete analysis for FNAM

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00

Price

View FNAM Analysis

See Change In Receivables data for all stocks →